Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Article in Leukemia & Lymphoma (August 2020)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Leukemia & Lymphoma (August 2020)
Article in Journal of Hematology & Oncology (November 2018)
Article in Expert Opinion on Biological Therapy (August 2018)